NCT02948608 is a clinical trial in Spondyloarthropathy, sponsored by Svendborg Hospital.

Who is sponsoring NCT02948608?

NCT02948608 is sponsored by Svendborg Hospital.

What condition does NCT02948608 study?

NCT02948608 studies Spondyloarthropathy.

Is NCT02948608 still recruiting?

NCT02948608 is currently status unknown. Last updated 7 March 2019.

Last reviewed 2019-03-07 · How we verify

NCT02948608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis

Status unknown Last updated 7 March 2019

What this trial tests

trial in Spondyloarthropathy in 60 participants. Status unknown.

Timeline

1 March 2017

Primary endpoint
31 March 2019

30 September 2019

Quick facts

Lead sponsor	Svendborg Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 March 2017
Primary completion	31 March 2019
Estimated completion	30 September 2019
Sites	1 location across Denmark

Conditions studied

Spondyloarthropathy — all drugs for Spondyloarthropathy →

Sponsor

Svendborg Hospital

Who can join

Adults 18 to 80, any sex, with Spondyloarthropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to investigate extra-articular manifestations, pain mechanisms, patient-reported outcomes, comorbidities and association between these conditions in patients with spondyloarthropathy (SpA) treated with Biologics. Further, to assess the predictive value of baseline pain profile on treatment outcome after ≥ 3 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study.
Andreasen RA, Kristensen LE, Ellingsen T, Christensen R, et al · · 2017 · cited 6× · PMID 28698330 · DOI 10.1136/bmjopen-2016-015536
The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study.
Andreasen RA, Kristensen LE, Egstrup K, Baraliakos X, et al · · 2021 · cited 1× · PMID 33918279 · DOI 10.3390/jcm10071469

Verify or expand the search:

Other Svendborg Hospital trials

Trials by the same sponsor.

NCT02956577 — Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02948608 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Svendborg Hospital
Last refreshed: 7 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02948608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing